Today, the U.S. Food and Drug Administration issued a Federal Register notice identifying nine bulk drug substances that the agency has considered and is proposing not to include on the list of bulk drug substances (or active pharmaceutical ingredients) that outsourcing facilitiesmay use in drug compounding under section 503B of the Federal Food, Drug & Cosmetic Act. The nine bulk drug substances are: dipyridamole, ephedrine sulfate, famotidine, hydralazine hydrochloride, methacholine chloride, sodium bicarbonate, sodium tetradecyl sulfate, trypan blue, and vecuronium bromide.
Each of these substances is an ingredient of one or more FDA-approved drug products. The nominations for these substances did not provide a reason why the FDA-approved drug products containing these substances could not be either used or adapted instead of compounding new drug products using bulk drug substances. To date, the agency has not found a clinical need for an outsourcing facility to use these bulk drug substances to compound finished products, which is the statutory standard for adding a bulk drug substance to the 503B bulks list. Therefore, the FDA is proposing to not include these substances on the 503B bulks list and we are seeking public comment before finalizing our decision.
The agency’s final guidance on this issue provides information regarding the analysis and processes the FDA intends to use to evaluate whether a bulk substance should be used by outsourcing facilities in compounding. As the FDA evaluates bulk drug substances, the agency intends to publish notices for public comment in the Federal Register that describe the FDA’s proposed position on each substance along with the rationale for that position.
Find details at:
| 
.png)
No hay comentarios:
Publicar un comentario